ATG4B and hepatocellular carcinoma: Taken together, these findings demonstrate that CRNDE promotes ATG4B-mediated autophagy, which alleviates the sensitivity of sorafenib in HCC cells, suggesting that the pathway CRNDE/ATG4B/autophagy may be a promising target to improve the sensitivity of sorafenib against HCC.